|1.||Kloosterboer, H J: 11 articles (05/2007 - 09/2000)|
|2.||Kloosterboer, Helenius J: 8 articles (12/2011 - 02/2004)|
|3.||Clarkson, Thomas B: 8 articles (07/2008 - 01/2002)|
|4.||Helmond, Frans A: 6 articles (10/2007 - 12/2003)|
|5.||Mol-Arts, Mirjam: 5 articles (01/2012 - 08/2008)|
|6.||Kenemans, Peter: 5 articles (01/2012 - 08/2008)|
|7.||Foidart, Jean-Michel: 4 articles (01/2012 - 01/2007)|
|8.||Kubista, Ernst: 4 articles (01/2012 - 07/2007)|
|9.||Nijland, E A: 4 articles (04/2009 - 10/2007)|
|10.||Seeger, H: 4 articles (10/2008 - 11/2001)|
08/30/2004 - "In conclusion, the results suggest that tibolone is a cardiovascular-safe treatment that is effective for the prevention of osteoporosis and that may have advantages over CEE or CEE + MPA with regard to endometrial and breast safety."
05/01/2004 - "Tibolone possesses estrogenic activity and is effective for treating the symptoms and osteoporosis associated with menopause. "
01/01/2003 - "Tibolone is a synthetic steroid effective for the treatment of climacteric symptoms and osteoporosis. "
06/01/1991 - "This study was conducted to evaluate the efficacy of a daily oral dose of 2.5 mg Org OD 14 ((7 alpha, 17 alpha)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one) in the treatment of established osteoporosis. "
03/01/2009 - "This Practice Point commentary discusses a double-blind, placebo-controlled trial by Cummings et al. that investigated the effects of tibolone 1.25 mg per day in 4,534 postmenopausal women (mean age 68 years) with osteoporosis. "
01/01/2012 - "When compared to equipotent doses of combined HT, tibolone reduced vaginal bleeding (15 RCTs, n = 6342; OR 0.32, 95% CI 0.24 to 0.42) but was less effective in relieving the frequency of vasomotor symptoms (two RCTs, n = 545; OR 4.16, 95% CI 1.50 to 11.58).As for long term safety, two major RCTs of tibolone versus placebo provided the most relevant data. "
01/01/2012 - "When compared to placebo, tibolone was more effective in relieving the frequency of vasomotor symptoms (two RCTs, n = 847; OR 0.42, 95% CI 0.25 to 0.69), although only the 2.5 mg/day dose of tibolone was significantly better than placebo; but with increased vaginal bleeding (seven RCTs, n = 7462; OR 2.75, 95% CI 1.99 to 3.80). "
08/01/2002 - "Treatment with tibolone led to a significantly lower bleeding rate during cycles 4-6 compared with CEE-MPA (15.0% vs 26.9%; P = 0.004); there was a similar difference during cycles 1-3. Both treatments improved QoL, wellbeing, climacteric symptoms and urogenital complaints. "
03/01/2002 - "Women treated with CEE/MPA or tibolone showed significant improvement of postmenopausal symptoms, including urogenital and sexual health symptoms, and had similar bleeding patterns after four cycles of therapy. "
08/01/2010 - "Recent studies show that, in comparison to HRT, tibolone is as effective in alleviating menopausal symptoms and preventing bone loss, has a greater positive effect on sexual dysfunction and is associated with less vaginal bleeding, but it is rarely mentioned in guidelines for menopausal treatment. "
|3.||Breast Neoplasms (Breast Cancer)
12/01/2011 - "The results of the LIBERATE trial show that tibolone is effective in symptomatic breast cancer patients and improves their quality of life. "
12/01/2011 - "Tibolone, a synthetic steroid, is effective in reducing these symptoms in healthy post-menopausal women, but this has never been studied in a large breast cancer population. "
12/01/2005 - "Tibolone was effective in the treatment of climacteric symptoms and well tolerated in a group of 52 women with a history of breast cancer. "
10/01/2006 - "On the other hand, although epidemiological studies show an increase in the risk of breast cancer among women treated with tibolone, accumulation of data obtained from radiological studies presents promising results. "
02/01/2009 - "Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial."
06/01/2012 - "The improvement in blood biochemistry, endometrial atrophy and maintenance of the anthropometrical measures reflected the safety of Tibolone use. "
11/01/2006 - "To demonstrate the safety and efficacy of tibolone (1.25 and 2.5 mg) in the treatment of moderate to severe vasomotor symptoms and symptoms associated with vaginal atrophy. "
11/01/2006 - "Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study."
08/01/2011 - "Tibolone administered in high dose and for a long period has a trophic effect, reversing vaginal atrophy, and has no dysplastic or neoplastic effect in the vagina of ovariectomized rats."
11/01/2006 - "Tibolone is effective and well tolerated for the treatment of moderate to severe vasomotor symptoms and the effects of vaginal atrophy associated with menopause."
01/01/2002 - "Triptoreline is a GnRHa which has been found to be effective in reducing myoma volume, but this effect could not be deactivated with tibolone. "
01/01/2000 - "Tibolone seems a valid alternative in menopausal patients with uterine myomas as it provides adequate relief from menopausal symptoms and avoids volume increase of the uterus and myomas."
01/01/2014 - "The median myoma volume decreased upon iCR by as much as -30% (P = 0.016) but increased upon tibolone by +4.7%. "
07/25/2002 - "There are no statistical significant differences between tibolone and transdermal hormonal replacement therapy regimens in respect to increase in the size of myoma uteri."
01/01/2002 - "The effects of add-back therapy with tibolone on myoma uteri."
|3.||Conjugated (USP) Estrogens (Premarin)
|7.||Medroxyprogesterone Acetate (Depo-Provera)
|10.||Gonadotropin-Releasing Hormone (GnRH)
|1.||Hormone Replacement Therapy (Therapy, Hormone Replacement)
|4.||Estrogen Replacement Therapy